BOLD - Boundless Bio, Inc. Common Stock
Boundless Bio, Inc. Common Stock Logo

BOLD - Boundless Bio, Inc. Common Stock

https://boundlessbio.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.

52W High
$4.72
52W Low
$1.00
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.21
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
11.40%
Institutions (25–75% balanced)
55.83%
Shares Outstanding
22,385,600
Float
16,462,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-2.48
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.43%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0004
Previous
-0.0019
Trend
Rising
Signal Cross
No cross
As of
Sep. 11, 2025